 |
Title 
|
|
|
|
Phase
|
|
|
|
Protocol
IDs
|
|
|
| |
06-882 A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
|
|
|
|
Phase II
|
|
|
|
NYU 06-882
SR06-937, NCT00696696
|
|
| |
1-methyl-d-tryptophan in Treating Patients With Relapsed or Refractory Solid Tumors
|
|
|
|
Phase I
|
|
|
|
VU-VICC-PHI-0814
VICCPHI0814, NLGC-NLG-2100, IRB#080257, VICTR-1855, NCT00788086
|
|
| |
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
|
|
|
|
Phase II
|
|
|
|
DB2-201
NCT00346281
|
|
| |
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
|
|
|
|
Phase I
|
|
|
|
OSU-05011
OSU-2005C0030, NCI-7044, 7044, NCT00288093
|
|
| |
3-Dimensional Conformal Radiation Therapy, Arterial Embolization, and Tumor Cell Vaccine in Treating Patients With Unresectable, Recurrent, or Metastatic Primary Liver Cancer or Pancreatic Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
UMDNJ-0120070076
0120070076, NCT00553683
|
|
| |
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
|
|
|
|
Phase II
|
|
|
|
BO21129
2007-003738-40, NCT00674973
|
|
| |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
|
|
|
Phase III
|
|
|
|
A6181114
NCT00428220
|
|
| |
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
|
|
|
|
Phase I
|
|
|
|
NO21895
2008-002298-11, NCT00773526
|
|
| |
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
|
|
|
|
Phase II
|
|
|
|
BO21128
2007-003751-37, NCT00652366
|
|
| |
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
|
|
|
|
Phase II
|
|
|
|
02-0580
NCT00660699
|
|
